Allogene Therapeutics earnings were -$252.3M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest ALLO earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$59.7M, down 0.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ALLO reported annual earnings of -$257.6M, with -21.3% growth.
Allogene Therapeutics Earnings Reports & History FAQ
What were Allogene Therapeutics's earnings last quarter?
On ALLO's earnings call on Invalid Date, Allogene Therapeutics (NASDAQ: ALLO) reported Q1 2025 earnings per share (EPS) of -$0.28, up 26.32% year over year. Total ALLO earnings for the quarter were -$59.73 million. In the same quarter last year, Allogene Therapeutics's earnings per share (EPS) was -$0.38.
Is Allogene Therapeutics profitable or losing money?
As of the last Allogene Therapeutics earnings report, Allogene Therapeutics is currently losing money. Allogene Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$252.32 million, a 13.68% decrease year over year.
What was ALLO's earnings growth in the past year?
As of Allogene Therapeutics's earnings date in Invalid Date, Allogene Therapeutics's earnings has grown year over year. ALLO earnings in the past year totalled -$252.32 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.